- Home
- GRND vs AKRO Comparison
GRND vs AKRO Comparison
Compare GRND & AKRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GRND
- AKRO
- Stock Information
- Founded
- GRND 2009
- AKRO 2017
- Country
- GRND United States
- AKRO United States
- Employees
- GRND N/A
- AKRO N/A
- Industry
- GRND Computer Software: Prepackaged Software
- AKRO Biotechnology: Pharmaceutical Preparations
- Sector
- GRND Technology
- AKRO Health Care
- Exchange
- GRND Nasdaq
- AKRO Nasdaq
- Market Cap
- GRND 4.3B
- AKRO 3.9B
- IPO Year
- GRND N/A
- AKRO 2019
- Fundamental
- Price
- GRND $21.16
- AKRO $51.69
- Analyst Decision
- GRND Strong Buy
- AKRO Strong Buy
- Analyst Count
- GRND 6
- AKRO 6
- Target Price
- GRND $23.50
- AKRO $82.50
- AVG Volume (30 Days)
- GRND 1.6M
- AKRO 1.6M
- Earning Date
- GRND 08-07-2025
- AKRO 08-08-2025
- Dividend Yield
- GRND N/A
- AKRO N/A
- EPS Growth
- GRND N/A
- AKRO N/A
- EPS
- GRND N/A
- AKRO N/A
- Revenue
- GRND $363,229,000.00
- AKRO N/A
- Revenue This Year
- GRND $28.97
- AKRO N/A
- Revenue Next Year
- GRND $21.80
- AKRO N/A
- P/E Ratio
- GRND N/A
- AKRO N/A
- Revenue Growth
- GRND 30.08
- AKRO N/A
- 52 Week Low
- GRND $10.26
- AKRO $21.34
- 52 Week High
- GRND $25.13
- AKRO $58.40
- Technical
- Relative Strength Index (RSI)
- GRND 37.31
- AKRO 45.35
- Support Level
- GRND $21.52
- AKRO $50.13
- Resistance Level
- GRND $22.64
- AKRO $53.60
- Average True Range (ATR)
- GRND 0.69
- AKRO 2.03
- MACD
- GRND -0.11
- AKRO -0.83
- Stochastic Oscillator
- GRND 8.50
- AKRO 6.37
About GRND Grindr Inc.
Grindr Inc is a social networking app for gay, bi, trans, and queer people. It is a social network that brings together gay and bisexual men who want to meet other men close to them in a completely discreet and anonymous way, without having to give any personal information or having to fill out a profile with confidential information in order to register.
About AKRO Akero Therapeutics Inc.
Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis (MASH), or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that have the potential to address the core processes underlying NASH pathogenesis.